BOTOX DAXXIFY

Daxxify™ (DaxxibotulinumtoxinA-lanm) – The Long-Lasting Botulinum Toxin for Facial Aesthetics

1. Overview & Manufacturer
Daxxify™ is a next-generation botulinum toxin type A developed by Revance Therapeutics, a U.S.-based biotechnology company. It was approved by the U.S. FDA in September 2022 for the temporary improvement of glabellar lines (frown lines between the eyebrows) in adults.

What makes Daxxify truly revolutionary is its extended duration of action—designed to last longer than traditional neuromodulators such as Botox®, Dysport®, and Xeomin®.

---

2. What Makes Daxxify Unique?

• ???? Peptide-stabilized formulation:
  Daxxify uses a proprietary peptide-excipient complex (RTP004) rather than human serum albumin for stabilization. This technology enhances binding and stability without relying on blood-derived proteins.

• ⏳ Longest-lasting results among all FDA-approved neuromodulators:

  • Clinical trials show median duration of ~6 months, and in some patients, effects can last up to 9 months

  • Reduces the need for frequent retreatments (2x/year vs. 3–4x with other brands)

---

3. Composition & Presentation

• Active ingredient: DaxxibotulinumtoxinA-lanm

• Supplied in single-use vials (40U or 100U)

• Lyophilized powder, requires reconstitution with 0.9% saline

---

4. Mechanism of Action
Daxxify works by blocking acetylcholine release at the neuromuscular junction, temporarily paralyzing specific muscles. This leads to:

• Relaxation of expression-related wrinkles

• Smoother skin in dynamic areas (e.g., glabella, forehead, crow’s feet)

• Potential muscle contouring or therapeutic benefits in the future (pending additional approvals)

---

5. FDA-Approved Indication

• Glabellar lines (frown lines) – Moderate to severe

Off-label uses (growing among aesthetic specialists):

• Forehead lines

• Crow’s feet

• Bunny lines

• Chin dimpling

• Masseter hypertrophy

• Neck lines and platysmal bands

Note: While off-label uses are widely practiced in aesthetic medicine, Daxxify is currently FDA-approved for glabellar lines only.

---

6. Clinical Benefits

---

7. Storage & Handling

• Store refrigerated at 2–8°C, but can be kept room temperature (≤25°C) for up to 72 hours before reconstitution

• After reconstitution, use within the timeframe indicated by Revance

• Gentle reconstitution; do not shake vigorously

---

8. Safety & Contraindications
Avoid in:

• Pregnant or breastfeeding patients

• Individuals with neuromuscular disorders (e.g., myasthenia gravis)

• Known allergy to any component of Daxxify

• Active infection or inflammation at the injection site

Most common side effects include:

• Mild headache

• Eyelid ptosis (temporary drooping)

• Injection site pain or redness